Back

Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk: the Essence-TIMI 73b trial

30 August 2025 (16:45 - 16:55)
Organised by: Logo
Congress Presentation Part of: HOT LINE 4 Drug therapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Brian Bergmark

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

11 More presentations in this session

Presentation thumbnail
BaxHTN – Efficacy and safety of the aldosterone synthase inhibitor baxdrostat in patients with uncontrolled or resistant hypertension
Professor B. Williams (London, GB)
Slides Video
Presentation thumbnail
Discussant review - BaxHTN
Professor T. Guzik (Edinburgh, GB)
Slides Video
Presentation thumbnail
Panel discussion - BaxHTN
Presentation thumbnail
KARDIA-3: Zilebesiran as Add-on Therapy in Adults with Hypertension and Established Cardiovascular Disease or at High Cardiovascular Risk
Doctor N. Pagidipati (Durham, US)
Slides Video
Presentation thumbnail
Discussant review - KARDIA-3
Professor M. Tomaszewski (Manchester, GB)
Slides Video

Access the full session

Session thumbnail
HOT LINE 4
Video

The Event

Event poster

ESC Congress 2025

30 August 2025 16:45 CET
You may be interested in
thumbnail
Congress Presentation
Presentation of the best paper published in the European Heart Journal in 2022: 'Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridemia and at high cardiovascular risk'
26 August 2023
thumbnail
Congress Presentation
Rationale and design of the SHASTA-3 and SHASTA-4 studies: randomized, double-blind, placebo-controlled, phase 3 studies of plozasiran in patients with severe hypertriglyceridemia
30 August 2024
thumbnail
Congress Presentation
ENTRIGUE: Pegozafermin for the treatment of severe hypertriglyceridemia.
26 August 2022
thumbnail
Congress Presentation
Transition of patients with familial chylomicronaemia syndrome from volanesorsen to olezarsen: safety and pharmacokinetic results
1 September 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources